Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

SANOFI : Combined General Shareholder Meeting of May 4, 2012

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/04/2012 | 07:35pm CET
PRESS RELEASE Combined General Shareholder Meeting of May 4, 2012

? Shareholder approval of the corporate and consolidated financial statements for 2011

? Dividend of ?2.65 per share payable as of May 15, 2012

? Nomination of a new director

? Partial renewal of the Board of Directors

Paris, France - May 4, 2012 - Sanofi (EURONEXT : SAN et NYSE : SNY) announced its Combined General Shareholder Meeting was held today at the Palais des Congrès in Paris. All resolutions were adopted by its shareholders.

During the meeting, shareholders approved, among other resolutions, the corporate and consolidated financial statements for the year 2011. At the General Meeting, shareholders decided the distribution of a dividend in the amount of ?2.65 per share that will be detached on Euronext Paris on May 10, 2012 with payment as of May 15, 2012.
The General Meeting also approved the appointment of Mr. Laurent Attal as a director for a term of four years, i.e., until the General Meeting called to approve the financial statements for the year
2015. Finally, Mr. Uwe Bicker, Mr. Jean-René Fourtou, Ms. Claudie Haigneré, Ms. Carole Piwnica and Mr. Klaus Pohle have each been reappointed for a term of four years.
After the Shareholder Meeting, the Board of Directors is comprised as follows:

? Serge Weinberg, Chairman of the Board of Directors

? Christopher Viehbacher, Chief Executive Officer

? Laurent Attal

? Uwe Bicker

? Robert Castaigne

? Thierry Desmarest

? Lord Douro

? Jean-René Fourtou

? Claudie Haigneré

? Igor Landau

? Suet-Fern Lee

? Christian Mulliez

? Carole Piwnica

? Klaus Pohle

? Gérard Van Kemmel

During the meeting, the shareholders approved the appointment of statutory and deputy auditors. The shareholders additionally ratified the move of the registered headquarters of Sanofi to 54, rue La Boétie, 75008 Paris. During the Board of Directors session following the meeting, Mr. Klaus Pohle was renewed as Chairman of the Audit Committee.

1/2

The voting results will be available on the company's website (www.sanofi.com) in the coming days.
The audiocast of the Combined General Shareholder Meeting is available on the Company's website (www.sanofi.com).

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Contacts:

Media Relations Investor Relations

Jean-Marc Podvin Sébastien Martel

+ (33) 1 53 77 46 46 + (33) 1 53 77 45 45 mr@sanofi.com ir@sanofi.com

2/2

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
05:27p NEW DENGUE HEMORRHAGIC FEVER FINDING : Insights from two large-scale phase III....
04:05p ZEALAND PHARMA AKTIESELSKABET : EU approval of Suliqua triggers USD 10 million m..
04:01p SANOFI : EU approval for Sanofi's type 2 diabetes treatment
11:15a GSK grabs Astra executive to replace pharma head
01/18 Global Influenza Market Has Been Accelerated USD 6.87 Billion in 2020
01/18 SANOFI : SuliquaTM Approved in the European Union for the Treatment of Adults wi..
01/18 SANOFI : EU approval of Suliqua(TM) triggers USD 10 million milestone payment to..
01/18 Drugmakers in Davos shift focus to chronic diseases of poor
01/17 SANOFI : SuliquaTM Approved in the European Union for the Treatment of Adults wi..
01/17 SANOFI : SuliquaTM Approved in the European Union for the Treatment of Adults wi..
More news
Sector news : Pharmaceuticals - NEC
04:33p Davos CEOs 'go local' on supply chain in Trump era
11:15a GSK grabs Astra executive to replace pharma head
10:40aDJGLAXOSMITHKLINE : Global Pharmaceuticals President Abbas Hussain to Leave -- Upd..
08:48aDJBusiness Watch -- WSJ
08:28aDJGLAXOSMITHKLINE : Global Pharmaceuticals President Abbas Hussain to Leave
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09:58a Reasons A Regeneron Pharmaceuticals Takeover Is Unlikely
01/18 Vet med industry now dominated by four firms; further mergers unlikely
01/18 New chief at Merrimack Pharma
01/18 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q4 2016 Update
01/17 MANNKIND : Afrezza Sales Start Off 2017 Modestly. Will A Bigger Sales Force Make..
Advertisement
Financials (€)
Sales 2016 36 734 M
EBIT 2016 9 202 M
Net income 2016 5 242 M
Debt 2016 6 114 M
Yield 2016 3,83%
P/E ratio 2016 16,82
P/E ratio 2017 15,05
EV / Sales 2016 2,86x
EV / Sales 2017 2,85x
Capitalization 98 840 M
More Financials
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 81,0 €
Spread / Average Target 5,8%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias E. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-0.52%105 178
JOHNSON & JOHNSON-0.44%312 045
ROCHE HOLDING LTD.1.29%203 230
PFIZER INC.-1.39%194 369
NOVARTIS AG-3.71%189 507
MERCK & CO., INC.3.91%168 654
More Results